Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and second leading cause of cancer related death worldwide...

Hepatocellular carcinoma (HCC) is lethal malignancy showing high relapse rates after curative resection in early-stage. Genomic features of stem cell-like cancer cells contributing aggressive tumor biology HCC remains unclear. The aim this study to understand underlying associated with stemness apply precise therapeutic strategies for resectable early-stage hepatocellular carcinoma. Using human...

Nonalcoholic fatty liver disease (NAFLD) is a spectrum that spans simple steatosis, fibrosis, and ultimately cirrhosis, leading cause of chronic globally. The severe variant NAFLD, non-alcoholic steatohepatitis (NASH), characterized by triglyceride accumulation within hepatocytes the subsequent inflammatory pathway activation, progressing to cirrhosis in 10%-20% patients. NASH known major risk ...

The sarcomatoid variant of hepatocellular carcinoma (HCC) is a rare histologic variant comprising malignant spindle cells and typical HCC. The proportion of the spindle cell component varies; when the tumor fully consists of malignant spindle cells, it is difficult to distinguish from various primary sarcomas. The 2010 World Health Organization classification of gastrointestinal tract tumors cl...

While a significant number of studies have focused on elucidating the functioning mechanisms Hepatocellular carcinoma (HCC) microenvironment, intercellular crosstalk between multiple cells in tumor microenvironment remains unclear. Here we co-cultured spheroids HCC cells, hepatic stellate (HSCs), and hepatocytes biomimetic composite hydrogel to construct 3D model vitro. The reproduced major cel...

Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality rate and limited treatment options. Recent research has brought attention to the significant importance of intercellular communication in progression HCC, wherein exosomes have been identified as critical agents facilitating cell-to-cell signaling. In this article, we investigate impact macrophages both sources targets...

Sorafenib, an oral multikinase inhibitor of Raf, VEGF and PDGF receptor signaling is approved for advanced hepatocellular carcinoma (HCC). One strategy to improve HCC therapy is to combine agents that target key signaling pathways. Aberrant mesenchymal-epithelial transition factor (c-Met) activation is associated with a variety of human malignancies and therefore represents a target for therapy...

Hepatoid adenocarcinoma (HAC) is a unique type of extrahepatic that histologically mimics the appearance hepatocellular carcinoma (HCC). stomach has poor prognosis with increased potential for liver metastasis. HCC and HAC share clinicopathological immunohistochemical features. The diagnosis metastatic hepatoid to challenging. It often misdiagnosed as carcinoma. diagnostic dilemma more

Successive current trials using immune response checkpoint blockade, the systemic therapy for progressive hepatocellular carcinoma (HCC) has shifted dramatically towards targeting tumor microenvironment (TME). Locoregional therapies (LRTs) like radiofrequency ablation (RFA)/rhizotomy, trans-arterial chemoembolization (TACE) and surgical resection in initial stages are critical. LRTs perform cru...

background: telomerase activity increases in cancer cells. bcl-2 is an antiapoptotic factor that its concentration grows in many cancer cells including hepatocellular carcinoma cells. in this study, an attempt was made to investigate the effects of a new synthetic compound, platinum azidothymidine (pt-azt) on treatment of rats with hepatocellular carcinoma (hcc) and to compare its effects with ...